Literature DB >> 3819787

Early sarcolemmal dysfunction in skeletal muscle amyloidosis.

C Doriguzzi, T Mongini, W Troni, G Monga.   

Abstract

Weakness and stiffness appeared in a 65-year-old man affected by multiple myeloma. Muscle fibre conduction velocity was recorded in situ in the biceps brachii and found to be significantly decreased. Muscle biopsy, performed in the same muscle, showed amyloid deposition and moderate atrophy of muscle fibres, which was not sufficient to explain the reduction in muscle fibre conduction velocity. The results of the study suggest that amyloid interferes with conduction along the sarcolemma and that this plays a pathogenetic role mainly in the early stages of the disease.

Entities:  

Mesh:

Year:  1987        PMID: 3819787     DOI: 10.1007/bf00314010

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

1.  Fluorescent stains, with special reference to amyloid and connective tissues.

Authors:  P S VASSAR; C F CULLING
Journal:  Arch Pathol       Date:  1959-11

2.  Skeletal muscle pseudohypertrophy in primary amyloidosis.

Authors:  J N Whitaker; K Hashimoto; M Quinones
Journal:  Neurology       Date:  1977-01       Impact factor: 9.910

3.  Primary amyloidosis of muscle.

Authors:  R K Lange
Journal:  South Med J       Date:  1970-03       Impact factor: 0.954

4.  [Sporadic, generalized pseudo-myopathy in primary endomysial vascular amyloidosis].

Authors:  J J Martin; L Van Bogaert; J Van Damme; J Peremans
Journal:  J Neurol Sci       Date:  1970-08       Impact factor: 3.181

5.  Interictal conduction slowing in muscle fibers in hypokalemic periodic paralysis.

Authors:  W Troni; C Doriguzzi; T Mongini
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

6.  Amyloid-associated muscle pseudohypertrophy.

Authors:  S P Ringel; H N Claman
Journal:  Arch Neurol       Date:  1982-07

7.  Amyloidosis: review of 236 cases.

Authors:  R A Kyle; E D Bayrd
Journal:  Medicine (Baltimore)       Date:  1975-07       Impact factor: 1.889

8.  Conduction velocity along human muscle fibers in situ.

Authors:  W Troni; R Cantello; I Rainero
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  Systemic amyloid myopathy--light-microscopic and fine-structural study of the skeletal muscles with histochemical and immunohistochemical study of amyloid.

Authors:  K Ii; K Hizawa; S Nunomura; H Morizumi
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

  9 in total
  4 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.

Authors:  Kensuke Shiga; Reiko Mizutani; Reina Isayama; Chihiro Shimazaki; Takahiko Tokuda; Masanori Nakagawa
Journal:  J Neurol       Date:  2010-07-08       Impact factor: 4.849

3.  Myopathy in primary systemic amyloidosis.

Authors:  M A Gertz; R A Kyle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

4.  Chronic myopathy due to immunoglobulin light chain amyloidosis.

Authors:  Irini Manoli; Justin Y Kwan; Qian Wang; Elisabeth J Rushing; Maria Tsokos; Andrew E Arai; Warner M Burch; Angela Dispenzieri; Alexandra C McPherron; William A Gahl
Journal:  Mol Genet Metab       Date:  2013-02-04       Impact factor: 4.797

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.